Studies reporting clinical outcome of karyotypically normal AML patients according to the MLL-PTD status: MLL-PTD+ versus MLL-WT
| Prognostic significance . | Independent prognostic factor on MVA . | AML type . | No. of pts (no. with/no. without alteration)* . | Age range, y (median) . | Median follow-up, mo . | Differences in pretreatment features . | Source . |
|---|---|---|---|---|---|---|---|
| CR rate: no significant difference (70% vs 71%) | — | De novo | 98 (11/87) | 18-84 (41/53)† | No significant differences | Caligiuri et al17 | |
| OS: no significant difference (median, 13.8 vs 20.1 mo) | — | 98 (11/87) | 27 | ||||
| CRD: significantly shorter for MLL-PTD+ pts (median, 7.1 vs 23.2 mo; P = .01) | ND | 68 (7/61) | 22 | ||||
| Median survival: significantly shorter for MLL-PTD+ pts (10 with normal and 5 with abnormal karyotype) compared with that of age-matched karyotypically normal control group (median, 5 vs 12 mo; P = .006) | ND | De novo and secondary | 45 (15/30) | 50-73‡ (61) | NR | NR | Schnittger et al84 |
| Relapse-free interval: significantly shorter for MLL-PTD+ pts (5 with normal and 4 with abnormal karyotype) compared with that of age-matched karyotypically normal control group (median, 4 mo vs median not reached; P < .001) | ND | 26 (9/17) | |||||
| CR rate: no significant difference (89% vs 78%) | — | De novo and secondary | 221 (18/203) | 16-60 (49/45)† | 19 | No significant differences | Döhner et al85 |
| OS: no significant difference (13.4 vs 20.8 mo) | — | 221 (18/203) | |||||
| CRD: significantly shorter for MLL-PTD+ pts (median, 7.75 vs 19 mo; P = .02) | Yes | 174 (16/158) | |||||
| DFS: no significant difference (median, 3.2 vs 19.6 mo) | — | De novo and secondary | 169 (8/161) | 16-60 (NR) | NR | NR | Steudel et al86 |
| EFS: significantly shorter for MLL-PTD+ pts (2-year EFS rates, 20% vs 66%; P = .03) | ND | De novo | 30 (5/25) | 16-60 (NR) | NR | NR | Muñoz et al89 |
| Prognostic significance . | Independent prognostic factor on MVA . | AML type . | No. of pts (no. with/no. without alteration)* . | Age range, y (median) . | Median follow-up, mo . | Differences in pretreatment features . | Source . |
|---|---|---|---|---|---|---|---|
| CR rate: no significant difference (70% vs 71%) | — | De novo | 98 (11/87) | 18-84 (41/53)† | No significant differences | Caligiuri et al17 | |
| OS: no significant difference (median, 13.8 vs 20.1 mo) | — | 98 (11/87) | 27 | ||||
| CRD: significantly shorter for MLL-PTD+ pts (median, 7.1 vs 23.2 mo; P = .01) | ND | 68 (7/61) | 22 | ||||
| Median survival: significantly shorter for MLL-PTD+ pts (10 with normal and 5 with abnormal karyotype) compared with that of age-matched karyotypically normal control group (median, 5 vs 12 mo; P = .006) | ND | De novo and secondary | 45 (15/30) | 50-73‡ (61) | NR | NR | Schnittger et al84 |
| Relapse-free interval: significantly shorter for MLL-PTD+ pts (5 with normal and 4 with abnormal karyotype) compared with that of age-matched karyotypically normal control group (median, 4 mo vs median not reached; P < .001) | ND | 26 (9/17) | |||||
| CR rate: no significant difference (89% vs 78%) | — | De novo and secondary | 221 (18/203) | 16-60 (49/45)† | 19 | No significant differences | Döhner et al85 |
| OS: no significant difference (13.4 vs 20.8 mo) | — | 221 (18/203) | |||||
| CRD: significantly shorter for MLL-PTD+ pts (median, 7.75 vs 19 mo; P = .02) | Yes | 174 (16/158) | |||||
| DFS: no significant difference (median, 3.2 vs 19.6 mo) | — | De novo and secondary | 169 (8/161) | 16-60 (NR) | NR | NR | Steudel et al86 |
| EFS: significantly shorter for MLL-PTD+ pts (2-year EFS rates, 20% vs 66%; P = .03) | ND | De novo | 30 (5/25) | 16-60 (NR) | NR | NR | Muñoz et al89 |
MLL-PTD+ indicates patients with partial tandem duplication of the MLL gene; MLL-WT, patients with wild-type MLL alleles; MVA, multivariable analysis; pts, patients; CR, complete remission; OS, overall survival; CRD, CR duration; DFS, disease-free survival; EFS, event-free survival; —, no significant difference in univariable analysis (MVA not performed); ND, not done; and NR, not reported.
Numbers of patients for whom clinical data were available.
Median age for patients with/patients without MLL-PTD.
Age range for patients with MLL-PTD.